Poolbeg Pharma plc – Interim Results for the six months to 30 June 2025
Well-funded with multiple upcoming clinical milestones
29 September 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces its unaudited interim results for the six months to 30 June 2025.
